Department of Dermatology and Allergy, University Hospital of Bonn, D-53127 Bonn, Germany; and
Christine Kühne-Center for Allergy Research and Education, CH-7265 Davos, Switzerland.
J Immunol. 2021 Feb 1;206(3):531-539. doi: 10.4049/jimmunol.2000667. Epub 2020 Dec 21.
Atopic dermatitis (AD) is a severe inflammatory skin disease. Langerhans cells and inflammatory dendritic epidermal cells (IDEC) are located in the epidermis of AD patients and contribute to the inflammatory processes. Both express robustly the high-affinity receptor for IgE, FcεRI, and thereby sense allergens. A beneficial role of vitamin D in AD is discussed to be important especially in patients with allergic sensitization. We hypothesized that vitamin D impacts FcεRI expression and addressed this in human ex vivo skin, in vitro Langerhans cells, and IDEC models generated from primary human precursor cells. We show in this article that biologically active vitamin D [1,25(OH)-D] significantly downregulated FcεRI at the protein and mRNA levels of the receptor's α-chain, analyzed by flow cytometry and quantitative RT-PCR. We also describe the expression of a functional vitamin D receptor in IDEC. 1,25(OH)-D-mediated FcεRI reduction was direct and resulted in impaired activation of IDEC upon FcεRI engagement as monitored by CD83 expression. FcεRI regulation by 1,25(OH)-D was independent of maturation and expression levels of microRNA-155 and PU.1 (as upstream regulatory axis of FcεRI) and transcription factors Elf-1 and YY1. However, 1,25(OH)-D induced dissociation of PU.1 and YY1 from the promotor, evaluated by chromatin immunoprecipitation. We show that vitamin D directly reduces FcεRI expression on dendritic cells by inhibiting transcription factor binding to its promotor and subsequently impairs IgE-mediated signaling. Thus, vitamin D as an individualized therapeutic supplement for those AD patients with allergic sensitization interferes with IgE-mediated inflammatory processes in AD patients.
特应性皮炎(AD)是一种严重的炎症性皮肤病。朗格汉斯细胞和炎症性树突状表皮细胞(IDEC)位于 AD 患者的表皮中,有助于炎症过程。两者都强烈表达 IgE 的高亲和力受体 FcεRI,从而感知过敏原。维生素 D 在 AD 中的有益作用被认为尤为重要,特别是在过敏致敏的患者中。我们假设维生素 D 会影响 FcεRI 的表达,并在人体离体皮肤、体外朗格汉斯细胞和源自人源前体细胞的 IDEC 模型中研究了这一点。我们在本文中表明,生物活性维生素 D[1,25(OH)2D]可显著下调 FcεRI 的蛋白和受体α链的 mRNA 水平,通过流式细胞术和定量 RT-PCR 进行分析。我们还描述了 IDEC 中功能性维生素 D 受体的表达。1,25(OH)2D 介导的 FcεRI 减少是直接的,导致 IDEC 在 FcεRI 结合后激活受损,如 CD83 表达所示。1,25(OH)2D 对 FcεRI 的调节独立于微 RNA-155 和 PU.1(作为 FcεRI 的上游调节轴)以及转录因子 Elf-1 和 YY1 的成熟和表达水平。然而,通过染色质免疫沉淀评估,1,25(OH)2D 诱导了 PU.1 和 YY1 从启动子上的解离。我们表明,维生素 D 通过抑制转录因子与其启动子的结合,直接减少树突状细胞上的 FcεRI 表达,从而损害 IgE 介导的信号转导。因此,作为对具有过敏致敏的 AD 患者的个体化治疗补充,维生素 D 会干扰 AD 患者中 IgE 介导的炎症过程。